215 million people under SUS universal coverage, the world's most genetically admixed major population, globally unique disease niches in Chagas and dengue, the hemisphere's largest sickle cell disease population outside Africa, and Latin America's most sophisticated academic research infrastructure across São Paulo, Rio, Belo Horizonte, and Porto Alegre.
Brazil is a federal republic of 215 million people; South America's largest nation and the world's seventh most populous country; spanning 8.5 million km² of diverse biomes from the Amazon rainforest and cerrado savannah to the Pantanal wetlands and Atlantic coast. A founding member of MERCOSUR, a BRICS nation, and a G20 economy, Brazil carries the strategic and demographic weight of a continent-defining country whose clinical research market has no peer in Latin America. São Paulo; the largest city in the Southern Hemisphere, with over 22 million people in its metropolitan area; is the overwhelming centre of Brazilian research activity, hosting Hospital das Clínicas FMUSP (Latin America's largest hospital complex), INCOR (the continent's pre-eminent cardiac research institution), and the Latin American headquarters of virtually every major global pharmaceutical and CRO company. Rio de Janeiro is the second major research corridor, anchored by Fiocruz; one of the Western Hemisphere's most important public health and tropical medicine research institutions; and the Instituto Nacional de Câncer (INCA). Belo Horizonte hosts Brazil's leading Chagas disease research programme through UFMG and the Evandro Chagas Institute connections. Porto Alegre is internationally recognised for cardiovascular and clinical trials research through Hospital de Clínicas de Porto Alegre (HCPA). Recife in the northeast carries global recognition for Zika, dengue, and maternal-fetal research. Salvador in Bahia anchors Afro-Brazilian health research in the state with Brazil's largest proportion of African-ancestry population.
Clinical trials are regulated by ANVISA (Agência Nacional de Vigilância Sanitária); Brazil's national health regulatory agency; under Resolution RDC 204/2017 and subsequent amendments, operating within a regulatory framework that incorporates ICH GCP E6(R2) principles; international sponsors submit clinical trial applications through ANVISA's online platform alongside the centralised Plataforma Brasil ethics system. Ethics review requires approval from both the institutional CEP (Comitê de Ética em Pesquisa) and, for Phase I studies and research involving special populations, the national CONEP (Comissão Nacional de Ética em Pesquisa). Brazil's SUS (Sistema Único de Saúde); the Unified Health System established as a constitutional right in 1988; provides universal health coverage for all 215 million Brazilians, creating a structured patient care pathway through Brazil's extensive network of public academic hospitals that makes the entire national population nominally accessible for clinical research through SUS-affiliated sites. The Brazilian pharmaceutical market is the fourth largest globally by prescription volume, and ongoing ANVISA regulatory reform initiatives have targeted faster approval timelines for priority therapeutic areas as Brazil works to enhance its competitiveness as a global clinical research destination.
Brazil is one of the world's most racially and genetically admixed nations; a consequence of five centuries of immigration and demographic mixing among Amerindian peoples (the pre-colonial population), Portuguese colonisers, enslaved Africans (approximately 4 million transported to Brazil in the largest transatlantic slave trade of any single country), and subsequent waves of European immigration (Italian, German, Spanish, Lebanese), Japanese immigration (São Paulo's Japanese-Brazilian community of ~1.5 million is the world's largest outside Japan), and ongoing immigration from across the globe. The result: approximately 49% of Brazilians identify as White (branco), 47% as pardo (mixed race: African, European, and Amerindian admixture), 9% as preto (Black, predominantly African ancestry), and 1.5% as Asian. The pardo population is one of the world's most genetically heterogeneous groups; carrying different proportions of European, African, and Amerindian ancestry depending on region (the northeast has higher African ancestry; the south has higher European ancestry; the north and Amazon basin have higher Amerindian ancestry). This ancestral complexity is pharmacogenomically significant: African-ancestry Brazilians carry variant allele frequencies in CYP2D6, CYP2C19, NAT2, G6PD, and other pharmacogenes that differ from European-ancestry populations in ways relevant to drug metabolism. The national median age is approximately 33 years. Investigator English proficiency is improving at major academic centres but remains variable; all regulatory submissions and patient-facing materials require Portuguese.
Brazil's disease burden reflects both the legacy of tropical infectious disease and the rapidly accelerating non-communicable disease transition of a rapidly urbanising middle-income country. Cardiovascular disease is the leading cause of death (~30% of mortality), with notable variation by ancestry; heart failure from Chagas cardiomyopathy is a distinct and quantitatively important contributor among Afro-Brazilians and populations from the endemic sertão region. Type 2 diabetes affects approximately 16–17% of Brazilian adults; one of the highest national prevalences globally; creating one of the world's largest absolute diabetic populations. Cancer is the second leading cause of death, with prostate cancer in Afro-Brazilian men occurring at rates significantly elevated relative to global averages. Dengue is hyperendemic and has generated some of the world's highest single-year case counts; Brazil has occasionally recorded more dengue cases than all other countries combined in peak epidemic years. Chagas disease, tuberculosis (Brazil is in the WHO top 30 high-burden list), leprosy (Brazil accounts for approximately 90% of new leprosy cases in the Americas), schistosomiasis (endemic in the northeast), and the emerging HIV epidemic concentrated in the northeast and among MSM complete a tropical infectious disease burden of global significance.
Chagas disease; the Americas' most distinctive research niche, concentrated entirely in Brazil: Chagas disease (American trypanosomiasis, caused by Trypanosoma cruzi) is a vector-borne parasitic infection transmitted primarily by triatomine bugs endemic to the Americas. Brazil carries the world's largest burden; an estimated 2–3 million Brazilians are currently infected, representing the largest single-country Chagas cohort on Earth. The disease's most devastating manifestation; Chagas cardiomyopathy; is the leading cause of infectious heart disease in the Western Hemisphere: approximately 30–40% of chronically infected individuals develop progressive cardiac damage, heart failure, arrhythmias, and thromboembolism in the absence of treatment. Benzimidazole (benznidazole and nifurtimox) remains the only approved anti-Trypanosoma therapy with limited efficacy in chronic-phase disease, meaning the treatment landscape is essentially undeveloped for the majority of affected patients. For any sponsor developing anti-Chagas trypanocidal drugs, cardiac therapies for Chagas cardiomyopathy, biomarker-guided treatment stratification tools, or novel pharmacological approaches to T. cruzi elimination, Brazil is not the preferred research platform; it is the only viable one. The Instituto Carlos Chagas (Fiocruz), UFMG's clinical Chagas programme, and specialist cardiac units managing Chagas cardiomyopathy in São Paulo, Belo Horizonte, and Goiânia provide the most experienced Chagas clinical research investigator communities on the planet. Brazil additionally hosts the world's largest sickle cell disease population outside sub-Saharan Africa; approximately 70,000–80,000 patients with SCD driven by the large African-ancestry population; creating a complementary rare disease research platform for haemoglobinopathy programs.
Brazil is Latin America's indispensable clinical research market; combining the patient scale of 215 million people, the world's most genetically admixed major population for pharmacogenomic diversity, globally unique disease niches (Chagas disease, sickle cell outside Africa, hemisphere's largest dengue burden), the hemisphere's most sophisticated academic research infrastructure, and per-patient costs well below North American and European equivalents, all accessible through the SUS universal health system that channels every Brazilian into the public hospital research network.
ANVISA with ICH GCP E6(R2)-aligned regulatory framework; Plataforma Brasil centralised ethics submission system (CEP + CONEP); ongoing ANVISA regulatory reform targeting reduced approval timelines for priority therapeutic areas; Brazil's Regulatory Improvement Programme increasing international regulatory recognition; Portuguese-language submissions required but major CROs and academic sites have established regulatory teams; ANVISA's Special Registration pathway for priority medicines applicable to breakthrough and rare disease programmes.
Per-patient and operational costs well below US, EU, and Australian equivalents; investigator fees, hospital overhead, and clinical research professional compensation substantially lower than North American markets; SUS public hospital infrastructure provides zero patient cost-sharing for trial-enrolled SUS patients; BRL competitive for USD/EUR-denominated budgets (with appropriate hedging for currency volatility); Latin America's largest CRO talent pool in São Paulo and Rio with competitive service rates; large patient pools enabling enrollment velocity that compounds per-patient savings.
215M people under SUS universal health coverage; Latin America's largest population by over 4x nearest competitor; world's most genetically admixed major population (African, European, Amerindian, Japanese components) for FDA/EMA diversity compliance; world's largest Chagas disease burden (~2–3M infected) for trypanocidal and cardiac programs; largest sickle cell disease population outside Africa for haemoglobinopathy trials; hemisphere's highest dengue case volumes; large treatment-naïve cardiovascular, diabetes, and cancer pools; African-ancestry participants providing diversity data unavailable in any comparable-income Western market.
Hospital das Clínicas FMUSP; Latin America's largest hospital complex; INCOR; the continent's premier cardiac research institution; Fiocruz; the Western Hemisphere's most important tropical medicine and vaccine research body; INCA; Brazil's national cancer research coordinator; HCPA Porto Alegre; internationally recognised for cardiovascular and clinical trial excellence; Latin America's largest CRO market with IQVIA, Parexel, ICON, Syneos, and PPD all operating major Brazilian offices; four nationally distributed academic research corridors (São Paulo, Rio, Belo Horizonte, Porto Alegre) providing geographic patient breadth.
Cardiovascular disease and metabolic medicine are Brazil's highest-volume commercial research pillars, anchored by INCOR's internationally connected cardiac research programme; whose Phase II–III portfolio in heart failure, arrhythmia, coronary disease, and hypertension is among the most productive in the Southern Hemisphere; and by the extraordinary Type 2 diabetes patient pools that Brazil's 16–17% adult prevalence creates across the country's SUS hospital network. Infectious disease carries Brazil's most globally distinctive scientific identity: Fiocruz's century-old tropical medicine research tradition, the Zika microcephaly cohort studies from Pernambuco that defined the global understanding of congenital Zika syndrome, the dengue burden that in peak years has exceeded the total case count of all other countries combined, and Chagas disease research that is uniquely and irreplaceably Brazilian. Oncology is the third major pillar; INCA's national cancer coordination, ICESP's São Paulo oncology platform, and the specific cancer disparities of the Afro-Brazilian population (elevated prostate cancer, aggressive breast cancer subtypes) creating Phase II–III oncology opportunities with the diversity dimensions that sponsors are increasingly required to demonstrate in global submissions. Rare and genetic diseases; sickle cell disease, Chagas cardiomyopathy as a cardiac rare disease, and several conditions with elevated prevalence in Brazil's indigenous and admixed populations; complete a therapeutic portfolio of extraordinary breadth for a single country. Mental health, respiratory medicine, vaccine research (building on Brazil's COVID-19 trial infrastructure and Fiocruz's vaccine development capabilities), and rheumatology/immunology each represent growing commercial research areas.
São Paulo dominates Brazilian clinical research, accounting for approximately 55–60% of national trial activity through its dense cluster of academic public hospitals and world-class private research institutions; the Hospital das Clínicas FMUSP complex alone rivals the research output of most national hospital systems. Rio de Janeiro provides the second corridor through Fiocruz's international platform and INCA's national cancer research mandate. Belo Horizonte, Porto Alegre, Recife, and Salvador each contribute distinct therapeutic and demographic specialisations that extend Brazil's research geography across five major regional corridors covering the country's continental breadth.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Hospital das Clínicas FMUSP (Complexo HCFMUSP) | São Paulo | Latin America's largest hospital complex; a cluster of specialised institutes and hospitals affiliated with the Universidade de São Paulo Faculty of Medicine, collectively managing approximately 2,200 beds and over 50,000 outpatient visits per day; Phase I–IV across every major therapeutic area; HCFMUSP encompasses INCOR (cardiac), ICESP (cancer), Instituto Central, Instituto de Psiquiatria, Instituto de Ortopedia, and over a dozen specialised units each maintaining independent Phase I–III commercial trial portfolios; the most internationally connected Brazilian trial site and the primary portal for global pharmaceutical sponsors activating the Brazilian research market. |
| 02 | INCOR; Instituto do Coração (Heart Institute, HCFMUSP) | São Paulo | Latin America's pre-eminent cardiac research institution and one of the hemisphere's most active Phase II–III cardiovascular trial sites; part of the HCFMUSP complex but with an independent research identity of international standing; Phase I–IV across heart failure, coronary artery disease, cardiac arrhythmia, hypertension, valvular disease, and cardiac device programs; INCOR's investigator community has been central to major international cardiovascular outcome trials and has published extensively in high-impact cardiology journals; particularly important for Chagas cardiomyopathy research; INCOR's Chagas Cardiomyopathy Programme provides specialist expertise in the cardiovascular manifestations of this Brazilian-endemic disease. |
| 03 | ICESP; Instituto do Câncer do Estado de São Paulo | São Paulo | São Paulo State's dedicated comprehensive cancer centre, operating as a joint HCFMUSP/FMUSP/SUS institution providing exclusive cancer treatment and research services; Phase I–IV across solid tumours (breast, lung, colorectal, prostate, and gynaecological cancers) and haematological malignancies; among the most active oncology Phase I–III sites in Latin America, with established international cooperative group connections and a growing Phase I oncology unit; ICESP's diversity advantage is particularly relevant for prostate cancer research given São Paulo's large Afro-Brazilian patient catchment, where the elevated prostate cancer incidence in African-ancestry men creates a globally underrepresented patient demographic for Phase III oncology diversity programs. |
| 04 | Hospital Israelita Albert Einstein | São Paulo | Brazil's most internationally recognised private hospital and one of Latin America's most sophisticated clinical research institutions; holds JCI accreditation and has been ranked among the world's best hospitals; Phase I–IV across oncology, cardiovascular, metabolic disease, neurology, and infectious disease; Albert Einstein's research department operates to international GCP standards with established multinational pharmaceutical company partnerships and a clinical research infrastructure; dedicated trial units, biobank, genomics centre, independent ethics committee; that rivals academic hospitals in high-income countries; its patient catchment from São Paulo's upper-middle-income population provides a demographically distinct Brazilian research population from SUS public hospitals. |
| 05 | Hospital Sírio-Libanês | São Paulo | One of Brazil's most internationally connected research hospitals and a major site for oncology, cardiovascular, and rare disease Phase II–IV programs; operates the Instituto de Ensino e Pesquisa (IEP) as a dedicated research centre with established pharmaceutical company partnerships; JCI-accredited private hospital with research infrastructure comparable to leading European private research hospitals; Sírio-Libanês' oncology and haematology research programmes are particularly active in precision medicine and immunotherapy programs where the hospital's comprehensive genomic profiling capability for Brazilian tumour samples enables biomarker sub-study data of global publication significance. |
| 06 | HC-UNICAMP (Hospital de Clínicas; Universidade Estadual de Campinas) | Campinas | UNICAMP's major academic hospital, located in Campinas; São Paulo State's second-largest city (~1.2 million); and an internationally active Phase II–III research site; affiliated with UNICAMP's Faculty of Medical Sciences, which has been a consistent top-10 Brazilian university in health research output; Phase II–IV across haematology (particularly haemoglobinopathy and sickle cell disease, for which UNICAMP's Haematology Centre is internationally recognised), oncology, metabolic disease, and internal medicine; UNICAMP's sickle cell disease research programme is among Brazil's most productive, making it the primary site for sponsors developing therapies for the world's largest SCD population outside sub-Saharan Africa. |
| 07 | INCA; Instituto Nacional de Câncer | Rio de Janeiro | Brazil's national cancer institute under the Ministry of Health, coordinating the national cancer control strategy and operating as the country's reference cancer treatment and research centre; Phase II–IV across all major solid tumour types and haematological malignancies; INCA's Phase III oncology portfolio is among the most active in Brazil and the most nationally representative; given its role as the country's cancer policy body; with established international cooperative oncology group connections through ECOG-ACRIN, EORTC, and other global networks; a critical site for sponsors requiring Brazilian national-level oncology trial activation and the endorsement of Brazil's cancer research establishment. |
| 08 | INI Fiocruz; Instituto Nacional de Infectologia Evandro Chagas | Rio de Janeiro | The clinical infectious disease research institute of Fiocruz; the Oswaldo Cruz Foundation; and one of the Western Hemisphere's most internationally cited tropical medicine clinical trial sites; Phase I–IV across HIV (Brazil's national antiretroviral therapy programme has been coordinated through Fiocruz networks), hepatitis, Chagas disease, dengue, Zika, leprosy, and emerging infectious diseases; INI Fiocruz's three-decade HIV clinical research tradition, its COVID-19 vaccine trial infrastructure (Brazil was a primary site for the AstraZeneca/Oxford and Janssen vaccine trials), and its WHO collaborating centre status create a research platform whose international regulatory credibility exceeds what GDP or market size would suggest; an essential partner for any sponsor conducting infectious disease Phase II–III programs requiring Brazilian regulatory engagement and WHO-recognised research infrastructure. |
| 09 | Hospital Universitário Clementino Fraga Filho (UFRJ) | Rio de Janeiro | The primary academic teaching hospital of the Universidade Federal do Rio de Janeiro (UFRJ) and a major Phase II–IV research site for the Rio de Janeiro public hospital network; oncology, haematology, infectious disease, cardiovascular, and internal medicine trial activity; the UFRJ Faculty of Medicine's research output in tropical medicine, haematology, and oncology reflects Rio de Janeiro's distinct disease profile; including a large Afro-Brazilian population in the Zona Norte and Baixada Fluminense communities; providing patient diversity complementary to the predominantly paulistano populations at São Paulo sites; an important node in the national clinical trial network for sponsors requiring Rio coverage within multi-site Brazilian trial designs. |
| 10 | HC-UFMG; Hospital das Clínicas da UFMG / Universidade Federal de Minas Gerais | Belo Horizonte | Minas Gerais State's major academic hospital and the primary research institution for the Chagas disease belt of central Brazil; UFMG Faculty of Medicine affiliate; Phase II–IV across cardiovascular (particularly Chagas cardiomyopathy; UFMG's Chagas disease clinical programme is the most active in Brazil outside Fiocruz), infectious disease, haematology, and oncology; Belo Horizonte's position in the heart of Brazil's historic Chagas endemic zone; where triatomine bug exposure was historically widespread before vector control programs; creates a regional Chagas patient catchment that is unmatched elsewhere in Brazil; an essential site for sponsors in Chagas cardiomyopathy, trypanocidal drug development, or cardiac therapies for Chagas heart disease. |
| 11 | HCPA; Hospital de Clínicas de Porto Alegre | Porto Alegre | Southern Brazil's premier academic hospital and one of Brazil's most internationally recognised clinical trial sites for cardiovascular, metabolic disease, and internal medicine research; UFRGS (Universidade Federal do Rio Grande do Sul) Faculty of Medicine affiliate; Phase I–IV with exceptional depth in cardiovascular medicine, endocrinology, diabetes, and nephrology; HCPA's predominantly European-ancestry patient catchment; Rio Grande do Sul State has Brazil's highest proportion of German and Italian descendants; creates a genetically distinct research population from São Paulo or Rio de Janeiro sites, enabling ancestry-stratified sub-group analyses within Brazilian multi-site trials; HCPA's research productivity per investigator is internationally cited as among Brazil's highest. |
| 12 | IMIP; Instituto de Medicina Integral Prof. Fernando Figueira | Recife | Pernambuco's major research institution and the site that gained global scientific recognition as the first centre to systematically characterise the Zika-microcephaly association in 2015–2016; publications from IMIP and its Pernambuco collaborators directly triggered the WHO Public Health Emergency of International Concern declaration for Zika; Phase II–IV across maternal-fetal medicine, infectious disease (Zika, dengue, flavivirus), paediatric conditions, and internal medicine; serves northeast Brazil's predominantly Afro-Brazilian and mixed-ancestry population in one of Brazil's most socioeconomically vulnerable regions; creating patient access to large treatment-naïve disease pools across infectious disease, maternal health, and cardiovascular indications that are epidemiologically distinct from São Paulo or Porto Alegre populations. |
| 13 | HUPES; Hospital Universitário Professor Edgard Santos (UFBA) | Salvador | The primary academic hospital of the Universidade Federal da Bahia (UFBA) in Salvador; Brazil's most African-ancestry city and the historical cultural capital of Afro-Brazilian culture; Phase II–III across cardiovascular disease, infectious disease, haematology, and internal medicine; Salvador's patient population has Brazil's highest proportion of African ancestry of any major city; approximately 80% of Salvador's residents identify as pardo or preto; creating the country's most concentrated Afro-Brazilian research catchment for sickle cell disease, cardiovascular health equity research, prostate cancer disparity trials, and pharmacogenomic studies in African-ancestry pharmacogene variants; an essential site for sponsors whose programs require African-ancestry participant data within a Brazilian regulatory framework. |
Latin America's largest hospital complex; a cluster of specialised institutes and hospitals affiliated with the Universidade de São Paulo Faculty of Medicine, collectively managing approximately 2,200 beds and over 50,000 outpatient visits per day; Phase I–IV across every major therapeutic area; HCFMUSP encompasses INCOR (cardiac), ICESP (cancer), Instituto Central, Instituto de Psiquiatria, Instituto de Ortopedia, and over a dozen specialised units each maintaining independent Phase I–III commercial trial portfolios; the most internationally connected Brazilian trial site and the primary portal for global pharmaceutical sponsors activating the Brazilian research market.
Latin America's pre-eminent cardiac research institution and one of the hemisphere's most active Phase II–III cardiovascular trial sites; part of the HCFMUSP complex but with an independent research identity of international standing; Phase I–IV across heart failure, coronary artery disease, cardiac arrhythmia, hypertension, valvular disease, and cardiac device programs; INCOR's investigator community has been central to major international cardiovascular outcome trials and has published extensively in high-impact cardiology journals; particularly important for Chagas cardiomyopathy research; INCOR's Chagas Cardiomyopathy Programme provides specialist expertise in the cardiovascular manifestations of this Brazilian-endemic disease.
São Paulo State's dedicated comprehensive cancer centre, operating as a joint HCFMUSP/FMUSP/SUS institution providing exclusive cancer treatment and research services; Phase I–IV across solid tumours (breast, lung, colorectal, prostate, and gynaecological cancers) and haematological malignancies; among the most active oncology Phase I–III sites in Latin America, with established international cooperative group connections and a growing Phase I oncology unit; ICESP's diversity advantage is particularly relevant for prostate cancer research given São Paulo's large Afro-Brazilian patient catchment, where the elevated prostate cancer incidence in African-ancestry men creates a globally underrepresented patient demographic for Phase III oncology diversity programs.
Brazil's most internationally recognised private hospital and one of Latin America's most sophisticated clinical research institutions; holds JCI accreditation and has been ranked among the world's best hospitals; Phase I–IV across oncology, cardiovascular, metabolic disease, neurology, and infectious disease; Albert Einstein's research department operates to international GCP standards with established multinational pharmaceutical company partnerships and a clinical research infrastructure; dedicated trial units, biobank, genomics centre, independent ethics committee; that rivals academic hospitals in high-income countries; its patient catchment from São Paulo's upper-middle-income population provides a demographically distinct Brazilian research population from SUS public hospitals.
One of Brazil's most internationally connected research hospitals and a major site for oncology, cardiovascular, and rare disease Phase II–IV programs; operates the Instituto de Ensino e Pesquisa (IEP) as a dedicated research centre with established pharmaceutical company partnerships; JCI-accredited private hospital with research infrastructure comparable to leading European private research hospitals; Sírio-Libanês' oncology and haematology research programmes are particularly active in precision medicine and immunotherapy programs where the hospital's comprehensive genomic profiling capability for Brazilian tumour samples enables biomarker sub-study data of global publication significance.
UNICAMP's major academic hospital, located in Campinas; São Paulo State's second-largest city (~1.2 million); and an internationally active Phase II–III research site; affiliated with UNICAMP's Faculty of Medical Sciences, which has been a consistent top-10 Brazilian university in health research output; Phase II–IV across haematology (particularly haemoglobinopathy and sickle cell disease, for which UNICAMP's Haematology Centre is internationally recognised), oncology, metabolic disease, and internal medicine; UNICAMP's sickle cell disease research programme is among Brazil's most productive, making it the primary site for sponsors developing therapies for the world's largest SCD population outside sub-Saharan Africa.
Brazil's national cancer institute under the Ministry of Health, coordinating the national cancer control strategy and operating as the country's reference cancer treatment and research centre; Phase II–IV across all major solid tumour types and haematological malignancies; INCA's Phase III oncology portfolio is among the most active in Brazil and the most nationally representative; given its role as the country's cancer policy body; with established international cooperative oncology group connections through ECOG-ACRIN, EORTC, and other global networks; a critical site for sponsors requiring Brazilian national-level oncology trial activation and the endorsement of Brazil's cancer research establishment.
The clinical infectious disease research institute of Fiocruz; the Oswaldo Cruz Foundation; and one of the Western Hemisphere's most internationally cited tropical medicine clinical trial sites; Phase I–IV across HIV (Brazil's national antiretroviral therapy programme has been coordinated through Fiocruz networks), hepatitis, Chagas disease, dengue, Zika, leprosy, and emerging infectious diseases; INI Fiocruz's three-decade HIV clinical research tradition, its COVID-19 vaccine trial infrastructure (Brazil was a primary site for the AstraZeneca/Oxford and Janssen vaccine trials), and its WHO collaborating centre status create a research platform whose international regulatory credibility exceeds what GDP or market size would suggest; an essential partner for any sponsor conducting infectious disease Phase II–III programs requiring Brazilian regulatory engagement and WHO-recognised research infrastructure.
The primary academic teaching hospital of the Universidade Federal do Rio de Janeiro (UFRJ) and a major Phase II–IV research site for the Rio de Janeiro public hospital network; oncology, haematology, infectious disease, cardiovascular, and internal medicine trial activity; the UFRJ Faculty of Medicine's research output in tropical medicine, haematology, and oncology reflects Rio de Janeiro's distinct disease profile; including a large Afro-Brazilian population in the Zona Norte and Baixada Fluminense communities; providing patient diversity complementary to the predominantly paulistano populations at São Paulo sites; an important node in the national clinical trial network for sponsors requiring Rio coverage within multi-site Brazilian trial designs.
Minas Gerais State's major academic hospital and the primary research institution for the Chagas disease belt of central Brazil; UFMG Faculty of Medicine affiliate; Phase II–IV across cardiovascular (particularly Chagas cardiomyopathy; UFMG's Chagas disease clinical programme is the most active in Brazil outside Fiocruz), infectious disease, haematology, and oncology; Belo Horizonte's position in the heart of Brazil's historic Chagas endemic zone; where triatomine bug exposure was historically widespread before vector control programs; creates a regional Chagas patient catchment that is unmatched elsewhere in Brazil; an essential site for sponsors in Chagas cardiomyopathy, trypanocidal drug development, or cardiac therapies for Chagas heart disease.
Southern Brazil's premier academic hospital and one of Brazil's most internationally recognised clinical trial sites for cardiovascular, metabolic disease, and internal medicine research; UFRGS (Universidade Federal do Rio Grande do Sul) Faculty of Medicine affiliate; Phase I–IV with exceptional depth in cardiovascular medicine, endocrinology, diabetes, and nephrology; HCPA's predominantly European-ancestry patient catchment; Rio Grande do Sul State has Brazil's highest proportion of German and Italian descendants; creates a genetically distinct research population from São Paulo or Rio de Janeiro sites, enabling ancestry-stratified sub-group analyses within Brazilian multi-site trials; HCPA's research productivity per investigator is internationally cited as among Brazil's highest.
Pernambuco's major research institution and the site that gained global scientific recognition as the first centre to systematically characterise the Zika-microcephaly association in 2015–2016; publications from IMIP and its Pernambuco collaborators directly triggered the WHO Public Health Emergency of International Concern declaration for Zika; Phase II–IV across maternal-fetal medicine, infectious disease (Zika, dengue, flavivirus), paediatric conditions, and internal medicine; serves northeast Brazil's predominantly Afro-Brazilian and mixed-ancestry population in one of Brazil's most socioeconomically vulnerable regions; creating patient access to large treatment-naïve disease pools across infectious disease, maternal health, and cardiovascular indications that are epidemiologically distinct from São Paulo or Porto Alegre populations.
The primary academic hospital of the Universidade Federal da Bahia (UFBA) in Salvador; Brazil's most African-ancestry city and the historical cultural capital of Afro-Brazilian culture; Phase II–III across cardiovascular disease, infectious disease, haematology, and internal medicine; Salvador's patient population has Brazil's highest proportion of African ancestry of any major city; approximately 80% of Salvador's residents identify as pardo or preto; creating the country's most concentrated Afro-Brazilian research catchment for sickle cell disease, cardiovascular health equity research, prostate cancer disparity trials, and pharmacogenomic studies in African-ancestry pharmacogene variants; an essential site for sponsors whose programs require African-ancestry participant data within a Brazilian regulatory framework.
These are the primary regulatory, academic, and industry bodies shaping Brazil's clinical research ecosystem.
Brazil's national health regulatory agency and the competent authority for clinical trial authorisation; regulatory framework incorporating ICH GCP E6(R2) principles under Resolution RDC 204/2017 and subsequent amendments; all trial applications submitted through ANVISA's online platform with supporting ethics documentation from Plataforma Brasil; ANVISA's ongoing regulatory improvement programme has included Special Registration pathways for priority medicines, reduced review timelines for certain therapeutic areas, and increased engagement with ICH regulatory harmonisation processes; a complex but improving regulatory environment whose challenges are justified by Brazil's unmatched patient scale and diversity for Latin American programs.
Brazil's national research ethics commission, operating under the National Health Council (Conselho Nacional de Saúde), providing national-level ethics review for Phase I studies, research involving special populations, and studies requiring CONEP review beyond local CEP approval; coordinates with institutional Comitês de Ética em Pesquisa (CEPs) through the Plataforma Brasil centralised submission system; Brazil's national digital ethics review platform that has streamlined submission processes and reduced administrative duplication across the multi-tiered review system; CONEP review is an additional step versus single-committee ethics systems in most other markets, but is navigable with established Brazilian regulatory expertise.
Brazil's Ministry of Health administers the SUS; the Unified Health System, established as a constitutional right in 1988; which provides universal health coverage for all 215 million Brazilians through a network of public hospitals, primary care units, and specialised centres; SUS-affiliated hospitals provide the patient care pathway infrastructure through which the vast majority of Brazil's clinical trial-accessible patients enter research programs; the Ministry's national disease programs (HIV/AIDS, TB, Chagas, dengue, sickle cell disease) provide the epidemiological data, patient registry infrastructure, and disease-specialist hospital networks that underpin Brazil's therapeutic area-specific research capabilities.
One of the Western Hemisphere's most important public health and biomedical research institutions; a century-old foundation under the Ministry of Health whose vaccine development, tropical medicine research, clinical trial infrastructure, and health surveillance programs have shaped hemispheric health outcomes; Fiocruz's clinical research capacity spans INI (infectious disease), Instituto Carlos Chagas (molecular biology and Chagas research in Curitiba), Instituto Evandro Chagas (Belém), and multiple other research units; produced COVID-19 vaccines, conducted landmark HIV, dengue, and Chagas clinical trials, and operates WHO collaborating centres across multiple health domains; an indispensable partner for any sponsor pursuing infectious disease, tropical medicine, or vaccine research in Brazil.
Brazil's most prestigious medical school and the institutional anchor of Hospital das Clínicas FMUSP, INCOR, and ICESP; produces the national clinical research investigator pipeline at scale; FMUSP's PhD and post-doctoral programmes in clinical medicine generate a continuously renewable pool of internationally trained Brazilian investigators available for commercial Phase II–III partnerships; Brazil's most prolific medical research publisher and the country's primary interface with international pharmaceutical industry research partnerships across oncology, cardiovascular, and metabolic medicine.
Brazil's national cancer institute under the Ministry of Health, serving as both the national cancer control policy body and the country's reference oncology research institution; coordinates the national oncology trial network across Brazilian research hospitals and provides the research policy framework within which commercial oncology trials operate in the Brazilian public health system; INCA's epidemiological surveillance data provides the cancer incidence and survival statistics used for trial feasibility assessments, and its established international cooperative group connections facilitate Brazilian participation in multinational Phase III oncology programs.
Latin America's pre-eminent cardiac research institution, operating within the HCFMUSP complex as a fully independent academic-clinical cardiac centre; an internationally recognised Phase II–III site for cardiovascular outcome trials with publication records in NEJM, Lancet, JAMA, and other high-impact journals; INCOR's Chagas cardiomyopathy programme is the most academically productive in the hemisphere, with established investigator networks across Brazil's Chagas endemic regions and a biobank of Chagas patient samples supporting biomarker research for novel therapeutic approaches to the leading infectious cause of heart disease in the Americas.
Global CRO with Brazil's largest CRO operations in Latin America; São Paulo headquarters managing Phase I–IV programs across oncology, cardiovascular, metabolic disease, infectious disease, and rare disease indications; ANVISA regulatory submission expertise, Plataforma Brasil CEP/CONEP navigation, and site activation support across the São Paulo, Rio, Belo Horizonte, and Porto Alegre academic hospital networks; real-world data and epidemiological analytics capability drawing on SUS administrative claims data; LATAM regional trial network coordination from São Paulo spanning Brazil, Argentina, Mexico, and Colombia within integrated Phase III programs.
International CRO with significant Brazilian operations supporting Phase II–IV oncology, cardiovascular, metabolic disease, and rare disease programs; established investigator relationships across HCFMUSP, INCOR, ICESP, Albert Einstein, Sírio-Libanês, and HCPA Porto Alegre; specialist Chagas disease and tropical medicine trial management capability; ANVISA regulatory strategy for sponsors using Brazil as the primary LATAM enrollment anchor; Portuguese-language documentation management and patient-facing material adaptation for the Brazilian regulatory environment.
Global CRO with Brazilian operations managing Phase II–III trial programmes across oncology, metabolic disease, cardiovascular, and rare disease indications; ANVISA submission expertise and Plataforma Brasil ethics navigation; established site networks across São Paulo, Rio de Janeiro, Belo Horizonte, and Porto Alegre academic hospital clusters; biostatistics and data management for Brazilian site trials with ancestry-stratified pharmacogenomic sub-group analysis for African, European, and Amerindian genetic components within Brazil's admixed population.
International biopharmaceutical solutions organisation with significant Brazilian operations providing integrated clinical development services across Phase I–IV; specialised capabilities in oncology, cardiovascular, and infectious disease programs that leverage Brazil's disease profile and patient population; strong Brazilian regulatory affairs expertise covering ANVISA submissions and the CONEP/CEP ethics approval pathway; Latin America regional network management from São Paulo coordinating Brazilian sites within broader LATAM programmes spanning Argentina, Colombia, Mexico, Chile, and Peru; growing presence in rare disease programs reflecting Brazil's unique SCD, Chagas, and NTD patient populations.
Brazil is Latin America's indispensable clinical research platform; the one country in the Western Hemisphere that combines population scale (215 million under SUS universal coverage), the world's most genetically admixed major population, a globally unique disease research niche in Chagas disease, the hemisphere's highest dengue burden, the world's largest sickle cell disease population outside sub-Saharan Africa, the continent's most sophisticated academic research infrastructure, and Latin America's most developed CRO market. The Chagas argument alone makes Brazil irreplaceable for an entire category of therapeutic development: the 2–3 million Brazilians infected with Trypanosoma cruzi, and the Chagas cardiomyopathy that develops in a third of them, exist in no other country at trial-recruitable scale; INCOR and UFMG's Chagas cardiac programmes are where the evidence base for treating the Americas' most common infectious heart disease will be built. Fiocruz's century of tropical medicine research leadership, its COVID-19 vaccine trial infrastructure, and its WHO collaborating centre network make it the only institution in the hemisphere capable of matching the tropical disease clinical research depth of Southeast Asia's MORU or RITM. Hospital das Clínicas FMUSP's scale; Latin America's largest hospital complex; and HCPA Porto Alegre's internationally benchmarked research productivity make Brazil capable of competing for global Phase III enrollment alongside European and North American sites. And 50%+ of Brazil's population carrying African ancestry creates a pharmacogenomic diversity opportunity; for sickle cell disease, cardiovascular health equity, prostate cancer disparities, and African-ancestry pharmacogene studies; that the Western Hemisphere cannot provide at equivalent scale anywhere else. ANVISA's regulatory complexity is real and demands experienced navigation, but every sponsor who has built Brazilian research infrastructure has found that the patient volumes, genetic diversity, and disease access that only Brazil provides ultimately justify the investment. No serious Latin American clinical development strategy is complete without Brazil at its centre.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.